Heparin-induced thrombocytopenia.
Research article published in Hematology/oncology clinics of North America (2007)
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that is characterized by platelet activation, hypercoagulability, and a resulting increased risk for thrombosis, both venous and arterial. This disorder is autoimmune-like, because the target antigen is a multimolecular complex of the "self" protein, platelet factor 4, and heparin. HIT usually begins 5 to 10 days after starting heparin, especially when administered intra- or perioperatively, although a rapid onset of thrombocytopenia can occur if heparin is given to a patient with circulating HIT antibodies that resulted from a recent heparin exposure. The clinical diagnosis is supported if heparin-dependent, platelet-activating antibodies are detectable. Treatment includes cessation of heparin and use of an alternative non-heparin anticoagulant, such as danaparoid, lepirudin, or argatroban. Warfarin must be avoided or postponed, as the acute phase of HIT poses a high risk for coumarin necrosis, particularly limb loss due to venous limb gangrene.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Heparin-induced thrombocytopenia.
Why This Matters for Hirudotherapy
This review examines the pathophysiology and treatment of heparin-induced thrombocytopenia (HIT), an immune-mediated adverse drug effect with a high risk of thrombosis. It discusses the cessation of heparin and the initiation of alternative anticoagulants, specifically mentioning lepirudin alongside danaparoid and argatroban. Because lepirudin is a recombinant derivative of the leech salivary anticoagulant hirudin, this study touches on the pharmaceutical legacy of leeches. Nevertheless, the article does not evaluate live leech therapy or natural secretome extracts, resulting in an indirect link to the core domain of hirudotherapy.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026